ArticleJournal of cardiothoracic surgery2026
Dual primary cancers of skin cancer and lung cancer: a case report.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report details a 76-year-old female patient presenting with a back mass and lung lesions. After a series of examinations and surgeries, she was diagnosed with dual primary cancers of skin (poorly differentiated squamous cell carcinoma) and lung (acinar adenocarcinoma and solid adenocarcinoma). The article discusses the diagnostic criteria, treatment options, and the importance of long - term follow - up for multiple primary cancers, highlighting the increasing incidence trend and relevant influencing factors.Given that cancer patients have a high risk of developing a second primary tumor, even if the primary tumor has undergone radical surgery, long - term and close follow - up is still necessary. During the follow - up process, attention should not only be paid to the changes in the organ where the primary tumor is located, but also to the abnormalities in other organs. Comparing pathological sections and combining molecular biological methods such as immunohistochemistry can help accurately identify the second primary cancer. For the treatment of the second primary cancer, the same principles as those for the first primary cancer should be followed, with radical surgical resection being the first choice. To improve the treatment effect, it is necessary to regularly monitor patients after the treatment of the first primary cancer, so as to detect the second primary cancer at an early stage, strive for early treatment opportunities, and thus improve the overall treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.